SCHEMBL6324760

SCHEMBL6324760

CCN(CC)C1CCN(C(=O)Cc2c(C)[nH]c(/C=C3\C(=O)Nc4cccc(-c5cccc(F)c5)c43)c2C)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.40
PDGFRB P09619 13/20 0.40
EGFR P00533 5/20 0.40
PDGFRA P16234 2/20 0.40
FGFR1 P11362 11/20 0.39
PRKAA1 Q13131 6/20 0.39
FLT1 P17948 5/20 0.39
FLT3 P36888 5/20 0.39
RET P07949 5/20 0.39
ALK Q9UM73 5/20 0.39
STK3 Q13188 4/20 0.39
AURKB Q96GD4 4/20 0.39
FLT4 P35916 4/20 0.39
LCK P06239 4/20 0.39
CSF1R P07333 4/20 0.39
PHKG2 P15735 4/20 0.39
FGFR3 P22607 4/20 0.39
AXL P30530 4/20 0.39
AURKA O14965 3/20 0.39
MAP4K2 Q12851 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323389 0.90 KDR (0.42) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6324754 0.90 KDR (0.42) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6329110 0.89 KDR (0.48) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6328924 0.89 FLT1 (0.40) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6319478 0.89 KDR (0.43) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6321553 0.85 KDR (0.41) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6322405 0.85 KDR (0.42) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6319633 0.84 KDR (0.52) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6327038 0.84 ALK (0.37) KDRPDGFRBEGFRPDGFRAFGFR1
SCHEMBL6321484 0.79 KDR (0.44) KDRPDGFRBEGFRPDGFRAFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885PDGFRB 575/4885EGFR 367/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885PDGFRB 575/4885EGFR 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.